Compare · IRON vs NVO
IRON vs NVO
Side-by-side comparison of Disc Medicine Inc. (IRON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 79.8x IRON ($2.17B).
- NVO has hit the wire 4 times in the past 4 weeks while IRON has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 20 for IRON).
- Company
- Disc Medicine Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.17B
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IRON
- Chief Executive Officer Quisel John D exercised 36,000 shares at a strike of $1.01, increasing direct ownership by 16% to 262,064 units (SEC Form 4)
- Director Bitterman Kevin exercised 27,136 shares at a strike of $45.07 and sold $1,902,505 worth of shares (27,136 units at $70.11) (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- Disc Medicine Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Director Bitterman Kevin sold $135,052 worth of shares (1,689 units at $79.96) as part of a pre-agreed trading plan (SEC Form 4)
- Director Bitterman Kevin sold $4,367,944 worth of shares (54,496 units at $80.15) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Disc Medicine Inc.
- SEC Form 144 filed by Disc Medicine Inc.
- SEC Form 144 filed by Disc Medicine Inc.
- SEC Form 144 filed by Disc Medicine Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank